New cholesterol-fighting drug slashes heart attack risk, but at a steep price; Amgen shares drop

http://www.cnbc.com/2017/03/17/amgens-cholesterol-fighting-drug-disappoints-shares-drop.html Traders are worried that Repatha isn't effective enough to justify the drug's hefty price tag of over $14,500 per year.